Zentek Ltd.

Equities

ZEN

CA98942X1024

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-04-23 pm EDT			5-day change	1st Jan Change
1.55 ^CAD	0.00%		0.00%	+6.90%

Apr. 03	Zentek Ltd. Enters into Definitive Distribution Agreement with Medwell Solutions LLC	CI
Mar. 25	Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial	MT

Zen Graphene Solutions Ltd. Reports Earnings Results for the Full Year Ended March 31, 2021

July 28, 2021 at 01:27 pm EDT

ZEN Graphene Solutions Ltd. announced earnings results for the full year ended March 31, 2021. For the full year, the company announced operating loss was CAD 4.322 million compared to CAD 1.677 million a year ago. Net loss was CAD 3.868 million compared to CAD 1.540 million a year ago. Basic loss per share from continuing operations was CAD 0.05 compared to CAD 0.02 a year ago.

Latest news about Zentek Ltd.

Zentek Ltd. Enters into Definitive Distribution Agreement with Medwell Solutions LLC	Apr. 03	CI
Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial	Mar. 25	MT
Zentek Announces Promising Preclinical Safety and Toxicity Results Achieved by Triera Biosciences Ltd. for C19hba	Mar. 25	CI
Zentek Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Sector Update: Health Care Stocks Edge Up Late Afternoon	Jan. 30	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Jan. 30	MT
Sector Update: Health Care	Jan. 30	MT
Zentek Shares Rise After Positive Preclinical Results For Covid Treatment Candidate	Jan. 30	MT
Zentek Announces "Positive" Therapeutic Results Achieved by Triera Biosciences for C19HBA	Jan. 30	MT
Zentek Brief: Announcing "Positive" Therapeutic Results achieved by Triera Biosciences for C19HBA	Jan. 30	MT
Zentek Ltd.'s Subsidiary Triera Biosciences Ltd. Completes Testing of Its C19HBA Aptamer as Potential Therapeutic	Jan. 30	CI
Zentek Ltd. Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters	Jan. 22	CI
Zentek Taps Independent Director as Board Chairman	Jan. 19	MT
Zentek Taps Independent Director as Board Chairman	Jan. 19	MT
Zentek Brief: Announcing Eric Wallman Appointed as Chairman of the Board	Jan. 19	MT
Zentek Ltd. Announces Board Changes	Jan. 19	CI
Zentek Launches Triera, a New Subsidiary, to Commercialize its Aptamer Covid-19 Treatment	Dec. 13	MT
Zentek Launches Triera Biosciences Ltd as its Wholly Owned Subsidiary	Dec. 13	CI
Zentek Signs Filter Distribution Deal With 1Click Heating; Shares Rise	Dec. 08	MT
Zentek Ltd. and 1Click Heating and Cooling Inc. Sign Distribution Agreement	Dec. 08	CI
Zentek's COVID-19 Aptamer Successfully Tested Against Omicron Variant in Pre-Clinical Study	Nov. 29	MT
Zentek Ltd. Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant	Nov. 29	CI
Zentek's CEO Appointed as Interim CEO of Albany Graphite Unit	Nov. 21	MT
Zentek Ltd. announced a financing transaction	Nov. 20	CI
Zentek Ltd. Appoints Mr. John Snisarenko to its Board of Directors	Nov. 15	CI

Chart Zentek Ltd.

Duration

Period

More charts

Company Profile

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Companyâs developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ZENTEK LTD.	+6.90%	114M
IQVIA HOLDINGS INC.	+3.13%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.49%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+8.26%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	11.94B
MEDPACE HOLDINGS, INC.	+32.83%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.01B

Other Biotechnology & Medical Research